“Computers were as good or better than doctors at detecting tiny lung cancers on CT scans, in a study by researchers from Google and several medical centers. The technology is a work in progress, not ready for widespread use, but thenew report, published in the journal Nature Medicine, offers a glimpse of the future of artificial intelligence in medicine.”
“One of the most promising areas is recognizing patterns and interpreting images — the same skills that humans use to read microscope slides, X-rays, MRIs, and other medical scans. By feeding huge amounts of data from medical imaging into systems called artificial neural networks, researchers can train computers to recognize patterns linked to a specific condition. Such as pneumonia, cancer, or a wrist fracture that would be hard for a person to see. The system follows an algorithm, or set of instructions, and learns as it goes. The more data it receives, the better it becomes at interpretation.”
“Each year, millions of Americans walk out of a doctor’s officewith a misdiagnosis. Physicians try to be systematic when identifying illness and disease, but bias creeps in. Alternatives are overlooked. Now a group of researchers in the United States and China has tested a potential remedy for all-too-human frailties: artificial intelligence.
“In a paper published in Nature Medicine, the scientists reported that they had built a system thatautomatically diagnoses common childhood conditions— from influenza to meningitis — after processing the patient’s symptoms, history, lab results, and other clinical data.”
“Recently, two AI drug design companies, Insilico Medicine and A2A Pharmaceuticals joined forces to bring to market a possible treatment for Duchenne muscular dystrophy (DMD) and other rare orphan diseases. Using AI to more rapidly discover optimal pre-clinical candidates may revolutionize the drug development process in the life sciences.”
“What AI can bring to the table is the ability to rapidly and accurately sort through massive amounts of data. This may very well revolutionize how competitive intelligence, drug discovery and stakeholder engagement take place as we know it. Among many functions that medical affairs is tasked with, an important one is stakeholder engagement with External Experts (EE) (formerly known as KOLs or Key Opinion Leaders). For Medical Science Liaisons (MSLs), who are the primary function engaging external stakeholders, there will likely be several changes.”